Phase 3 N=217 To Evaluate Sarilumab - SAR153191 (REGN88) - Auto-injector Device In Patients With Rheumatoid Arthritis
RA
Primary: Number of Validated AID Associated Product Technical Failures (PTFs) — 0; 0 PTFs
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=320 Radiation + Cisplatin or Panitumumab in Locally Advanced Stage III or Stage IV Head and Neck Cancer
Head and Neck Cancer
Primary: Progression-free Survival (PFS) Rate — 50; 43; 110; 117 Participants — p=0.83
Phase 3 N=417 HX575 Epoetin Alfa Subcutaneously (s.c.) in Chronic Kidney Disease (CKD)
Chronic Kidney Disease
Primary: Anti-Erythropoietin (EPO) Antibodies — 1.7 percentage of participants
Phase 3 N=116 Tranexamic Acid in Reverse Total Shoulder Arthroplasty
Shoulder Joint Disease · Complications; Arthroplasty · Intraoperative Complications
Primary: Total Blood Loss — 1122.4; 1472 Total Blood Loss (mL)
Phase 3 N=150 A Study on Safety and Efficacy of Tocilizumab (RoActemra/Actemra) Alone or in Combination With Non-Biologic Antirheumatics in Participants With Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Percentage of Participants With Adverse Events — 91.3 percentage of participants
Phase 3 N=320 A Study for Evaluation of GSK Biologicals' Pandemic Influenza Vaccine.
Influenza
Primary: Titers for Serum H5N1 Haemagglutination-inhibition (HI) Antibodies — 739.5; 621.7 Titers
Phase 3 N=383 Everolimus in de Novo Kidney Transplant Recipients
Kidney Transplantation
Primary: Percentage of Participants Without Wound Healing Complications - Worst-case Scenario — 68.39; 61.58 Percentage of participants — p=0.0921
Phase 3 N=316 Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Neulasta®
Neutropenic Complications · Breast Neoplasms · Chemotherapy-induced Neutropenia
Primary: Mean Duration of Severe Neutropenia (DSN) During Cycle 1 of Chemotherapy — 0.75; 0.83; 0.75; 0.79 days — p=0.05
Phase 3 N=44 Proton/Photon Rt - Benign Meningiomas(P92-13)
Benign Meningioma
Primary: Progression Free Survival — 91; 91; 86; 81 percentage of participants surviving — p=0.234
Phase 3 N=549 Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma
Medulloblastoma
Primary: Event-free Survival (EFS) — 76.3; 84.9; 85.8; 85.8 probability of 3 year EFS
Phase 3 N=61 Adding Cognitive Behavioral Therapy to Drug Treatment for Social Anxiety Disorder
Social Anxiety Disorder
Primary: Liebowitz Social Anxiety Scale (LSAS) — 7.77; 7.84 units on a scale — p=.267
Phase 3 N=240 The Mycotic Ulcer Treatment Trial II: A Randomized Trial Comparing Oral Voriconazole vs Placebo
Corneal Ulcer · Eye Infections, Fungal
Primary: Incidence of Perforation or Therapeutic Penetrating Keratoplasty — 0.0095562; 0.011204 New perforations or TPK/person-days — p=0.29
Phase 3 N=275 Safety and Efficacy Study of SHP465 in Adults Aged 18-55 Years With Attention-deficit/ Hyperactivity Disorder (ADHD)
Attention Deficit Hyperactivity Disorder (ADHD)
Primary: Change From Baseline in the Adult Attention-deficit/Hyperactivity Disorder Rating Scale-4 (ADHD-RS) With Prompts Total Score at Visit 6 (Week 4) — 40.5; 39.8; 39.9…
Phase 3 N=200 Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers
Diabetic Foot Infection
Primary: Number of Participants With Clinical Response — 56; 54 Participants
Phase 3 N=50 Mifepristone Versus Osmotic Dilator Insertion for Cervical Preparation Prior to Surgical Abortion at 15-18 Weeks
Cervical Preparation
Primary: Length of Procedure — 14; 13.5 minutes